NCT00754949

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sun Pharmaceutical Industries Limited · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.

Conditions

• Blepharoconjunctivitis

Interventions

Type	Name	Description
DRUG	1% Azithromycin and 0.1% Dexamethasone	Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
DRUG	1% Azithromycin	Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
DRUG	0.1% Dexamethasone	Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

Timeline

• First posted: 2008-09-18
• Last updated: 2021-11-22